NEUROONE MEDICAL TECHNOLOGIES (NMTC) Company Report

NeuroOne Medical Technologies Corporation reported a 163% increase in product sales to $9.1 million for fiscal year 2025 and a 907% increase in product revenue to $2.7 million for the fourth quarter of fiscal 2025.
The company significantly improved its product gross margins to 56.5% for fiscal year 2025 and 55.8% for Q4 2025, while also reducing total operating expenses by 5% for the full fiscal year and 2% for the fourth quarter.
NeuroOne achieved key operational milestones, including FDA 510(k) clearance for the OneRF trigeminal nerve ablation system and successful treatment of the first two patients with this system.
The company strengthened its balance sheet with an $8.2 million capital raise, ending Q4 2025 with $6.6 million in cash and cash equivalents and $7.9 million in working capital.
Nasdaq granted NeuroOne a 180-day extension until May 4, 2026, to regain compliance with its minimum bid price rule.

8 hours ago

Transcript

NeuroOne Medical Technologies Reports Strong FY 2025 Financial Growth and Key Operational Milestones

NMTC

Earnings

Product Launch

Delisting/Listing Issues

NeuroOne Medical Technologies Corporation (NMTC) reported a 163% increase in product sales to $9.1 million for fiscal year 2025, with product gross margins improving to 56.5%. For Q4 2025, product revenue surged 907% to $2.7 million with gross margins at 55.8%.
The company significantly reduced its net loss, improving by 71% to $3.6 million (or $0.09 per share) for FY 2025 and by 52% to $1.6 million (or $0.03 per share) for Q4 2025.
Operationally, NMTC received FDA 510(k) clearance for the OneRF trigeminal nerve ablation system in FY 2025, with the first two patients successfully treated in Q4 2025. The company also initiated the process for ISO 13485 certification for international expansion.
As of September 30, 2025, the balance sheet was strengthened with $6.6 million in cash and cash equivalents and $7.9 million in working capital, with no outstanding debt. Additionally, Nasdaq granted a 180-day extension until May 4, 2026, for compliance with the minimum bid price rule.

8 hours ago

Transcript

NeuroOne Medical Technologies Reports Record Fiscal Year 2025 Results and Q4 2025 Revenue Growth

NMTC

Earnings

Revenue Acceleration/Inflection

Delisting/Listing Issues

NeuroOne Medical Technologies Corporation reported a record fiscal year 2025, with product sales growing 163% to $9.1 million and product gross margins improving to 56.5%.
In Q4 2025, product revenue increased 907% to $2.7 million, and the net loss improved 52% to $1.6 million, or $0.03 per share.
The company received FDA 510(k) clearance for its OneRF trigeminal nerve ablation system, with the first two patients successfully treated in Q4 2025.
NeuroOne strengthened its balance sheet with an $8.2 million capital raise, ending fiscal year 2025 with $6.6 million in cash and cash equivalents and $7.9 million in working capital.
Nasdaq granted the company a 180-day extension until May 4, 2026, to regain compliance with the minimum bid price rule for continued listing.

9 hours ago

Transcript

NeuroOne Medical Technologies Corporation Reports Strong Q4 and Full Year Fiscal 2025 Results

NMTC

Earnings

Revenue Acceleration/Inflection

Product Launch

NeuroOne Medical Technologies Corporation reported product revenue of $2.7 million for the fourth quarter of fiscal 2025, representing a 907% increase compared to the prior year, and $9.1 million for the full fiscal year 2025, a 163% increase.
The company achieved a product gross margin of 55.8% in Q4 fiscal 2025 and 56.5% for the full fiscal year 2025, while operating expenses decreased by 4.6% to $12.4 million for the full fiscal year.
Net loss improved by 71% to $3.6 million or ($0.09) per share for the full fiscal year 2025.
Operationally, NeuroOne received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System, successfully treated the first two facial pain patients, and expanded its distribution agreement with Zimmer Biomet, securing a $3 million upfront payment. The company ended fiscal 2025 with $6.6 million in cash and cash equivalents.

10 hours ago

8-K

NeuroOne Medical Technologies Reports Fiscal Year 2025 Preliminary Results and Strategic Updates

NMTC

Guidance Update

Product Launch

Revenue Acceleration/Inflection

NeuroOne Medical Technologies reported preliminary fiscal year 2025 product revenue of $9.1 million, marking a 163% increase year-over-year and meeting its guidance.
The company also recognized $3 million in license revenue from an expanded exclusive distribution agreement with Zimmer Biomet.
As of September 30, 2025, NeuroOne had $6.6 million in cash and cash equivalents and believes it is funded through at least fiscal 2026.
The company received FDA clearance for its OneRF TN system to treat trigeminal neuralgia, with a limited launch targeted for November.

Oct 7, 2025, 12:30 PM

Transcript

NeuroOne Announces Preliminary Unaudited Fiscal Year 2025 Results

NMTC

Earnings

Revenue Acceleration/Inflection

Guidance Update

NeuroOne Medical Technologies Corporation (NMTC) announced preliminary unaudited product revenue of $9.1 million for the fiscal year ended September 30, 2025.
This represents a 163% increase compared to $3.5 million in product revenue for fiscal year 2024.
The company reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025.
The revenue growth was primarily driven by expanded customer interest and positive outcomes with the OneRF® Ablation system.
NeuroOne will host a virtual investor webinar on October 7, 2025, at 8:30 a.m. EST to discuss business operations and provide a financial overview.

Oct 6, 2025, 8:19 PM

8-K

NeuroOne Medical Technologies Provides Fiscal Year 2025 Revenue Guidance and Product Updates

NMTC

Guidance Update

Product Launch

New Projects/Investments

NeuroOne Medical Technologies (NMTC) provided fiscal year 2025 revenue guidance of $8 to $10 million and increased its product gross margin guidance to a range of 50% to 53%.
The company is funded through at least fiscal year 2026 and remains debt-free, having raised $8.2 million in net proceeds in April and holding $8 million in cash as of the end of June.
NMTC recently received FDA clearance for its OneRF ablation system for facial pain (trigeminal neuralgia), with a limited market evaluation expected to begin in November.
The company has four FDA-cleared products and maintains exclusive partnerships with the Mayo Clinic and Zimmer Biomet, the latter of which invested $8.5 million for licensing rights and commercializes NMTC's diagnostic and ablation system for brain use.

Sep 17, 2025, 4:15 PM

Transcript

NeuroOne Receives FDA Clearance for OneRF® Trigeminal Nerve Ablation System

NMTC

Product Launch

New Projects/Investments

NeuroOne Medical Technologies Corporation has received U.S. Food and Drug Administration (FDA) clearance to market its OneRF® Trigeminal Nerve Ablation System.
This system is cleared for use in procedures to create radiofrequency lesions for the treatment of pain or for lesioning nerve tissue for functional neurosurgical procedures.
The company targets a limited commercial launch in the fourth quarter of calendar 2025.
The OneRF® Trigeminal Nerve Ablation System treats trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people in the United States annually.
NeuroOne expects to begin generating revenues from trigeminal nerve ablation as soon as late calendar year 2025.

Aug 18, 2025, 12:30 PM

Press Release

NeuroOne posts Q2 2025 earnings results

NMTC

Earnings

Revenue Acceleration/Inflection

Product Launch

Strong revenue and margin performance: In Q2 2025, product revenue was steady at $1.4 million while first-half product revenue surged 97% to $4.7 million with gross margins rising to 57.9%, indicating significant operational improvements.
Strategic partnership benefits: The collaboration with Zimmer Biomet delivered a $3 million upfront license fee, underpinning revenue growth and setting the stage for FDA clearance on a new trigeminal nerve ablation system.
Robust financial positioning: The company remains debt-free and bolstered its balance sheet with an $8.2 million capital raise, providing funding through at least fiscal 2026.
Clinical and leadership advancements: Positive clinical outcomes, highlighted by a patient nearing one year seizure-free, and the recent appointment of a new Chief Medical Adviser support continued innovation and market expansion.

May 13, 2025, 12:31 PM

Transcript

NeuroOne Medical Technologies Announces Public Equity Offering

NMTC

Underwriting Agreement executed on April 4, 2025 with Ladenburg Thalmann for the public offering of 16,000,000 shares with an option to purchase an additional 2,400,000 shares at $0.50 per share.
Legal opinion from Honigman LLP confirms that the offered shares have been duly authorized, fully paid, and validly issued pursuant to the terms set forth in the registration documents.
The offering closed on April 7, 2025, resulting in 49,797,000 shares outstanding, with net proceeds intended for general working capital.